On October 17, 2025, Oaktree Acquisition Corp. III Life Sciences announced the appointment of Dr. David A. Berry as an independent director. Dr. Berry will also serve on the audit, nominating, and compensation committees.
IndividualDavid A. Berry, MD, PhDRoleIndependent DirectorType of ChangeAppointedEffective DateOctober 17, 2025ReasonNot disclosedReplacement InfoN/ABackground DetailsCo-founder of Averin Capital, former CEO of Valo Health, extensive board experienceBoard/Committee Role ChangesAppointed to audit, nominating, and compensation committeesOriginal SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.